CRISPRcon Midwest: Chuck Klosterman to give the keynote address
CRISPRcon: Conversations on Science, Society & the Future of Gene Editing will host its first regional event this fall to bring diverse voices together to discuss societal considerations for the future of CRISPR and other gene editing technologies.
CRISPRcon Midwest will be at the University of Wisconsin–Madison on October 8. The forum will feature an exciting and thought-provoking lineup of panel discussions, keynotes, interactive discussions, and networking opportunities. Join us to explore critical questions about patents and ownership; genomic difference and health disparities; agriculture and sustainability; the role of scientists in public debate; and more.
Noted author and pop-culture critic Chuck Klosterman will give a keynote address.
Klosterman is the best-selling author of eight nonfiction books (most notably “Sex, Drugs, and Cocoa Puffs” and “But What If We’re Wrong?”) and three works of fiction (most recently the short story collection “Raised in Captivity”). He has written for the Washington Post, The New York Times, SPIN, Esquire, GQ, The Guardian, The Believer, Billboard, The Onion’s A.V. Club, and ESPN, and he served as The Ethicist for The New York Times Magazine for three years. A native of North Dakota, he lives in Portland with his wife and two kids.
Other confirmed speakers include farmers, social scientists, ethicists, environmentalists, indigenous advocates, patient advocates, gene editing researchers, religious scholars, business leaders, policy experts, human rights experts, and more.
Attendees will also have the opportunity to shape and lead the event’s dynamic conversations during the lunchtime Ideas Marketplace session.
CRISPRcon sparks curiosity, builds understanding, and highlights societal histories and other context relevant to decisions on gene editing technologies. CRISPRcon is a program of the nonprofit, non-advocacy Keystone Policy Center, established in 1975. This event will be hosted by the University of Wisconsin-Madison and is being developed in partnership with the university and the CRISPRcon Advisory Council.